These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 10886583)

  • 1. Need for an incentive-based reimbursement policy toward quality care for dialysis patient management.
    Hidai H
    Kidney Int; 2000 Jul; 58(1):363-73. PubMed ID: 10886583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
    Bhat P; Bhat JG
    Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
    [No Abstract]   [Full Text] [Related]  

  • 3. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
    Nissenson AR; Mayne TJ; Krishnan M
    Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
    [No Abstract]   [Full Text] [Related]  

  • 4. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization.
    Lacson E; Hakim RM
    Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423
    [No Abstract]   [Full Text] [Related]  

  • 5. The 2011 ESRD prospective payment system: an uncontrolled experiment.
    Winkelmayer WC; Chertow GM
    Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428
    [No Abstract]   [Full Text] [Related]  

  • 6. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2011 ESRD prospective payment system: welcome to the bundle.
    Weiner DE
    Am J Kidney Dis; 2011 Apr; 57(4):539-41. PubMed ID: 21333431
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2017 Nov; 82(210):50738-97. PubMed ID: 29091373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization.
    Johnson DS; Meyer KB; Johnson HK
    Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes to the end-stage renal disease quality incentive program.
    Fishbane S; Miller I; Wagner JD; Masani NN
    Kidney Int; 2012 Jun; 81(12):1167-71. PubMed ID: 22534963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular access for HD: aligning payment with quality.
    Amedia CA; Bolton WK; Cordray T; Hakim R; Howard R; Jackson J; Kulawik D; Lyon M; Mahoney D; Messana A; Nissenson A; Oviatt L; Parlato D; Roddy S; Solid C
    Semin Dial; 2011; 24(1):37-40. PubMed ID: 21338392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Financial incentives and dialysis].
    Keller F; Dress H; Mertz A; Marckmann G
    Med Klin (Munich); 2007 Aug; 102(8):659-64. PubMed ID: 17694285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Freestanding Dialysis Facility Size and Medicare Quality Incentive Program Performance Scores.
    Ajmal F; Probst J; Brooks J; Hardin J; Qureshi Z
    Am J Nephrol; 2019; 49(1):64-73. PubMed ID: 30557871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing VA and private sector healthcare costs for end-stage renal disease.
    Hynes DM; Stroupe KT; Fischer MJ; Reda DJ; Manning W; Browning MM; Huo Z; Saban K; Kaufman JS;
    Med Care; 2012 Feb; 50(2):161-70. PubMed ID: 21945972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward population management in an integrated care model.
    Maddux FW; McMurray S; Nissenson AR
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):694-700. PubMed ID: 23539229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Nov; 77(218):67450-531. PubMed ID: 23139948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients.
    Hsieh HM; Lin MY; Chiu YW; Wu PH; Cheng LJ; Jian FS; Hsu CC; Hwang SJ
    Nephrol Dial Transplant; 2017 Jul; 32(7):1184-1194. PubMed ID: 28486670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation].
    Blotière PO; Tuppin P; Weill A; Ricordeau P; Allemand H
    Nephrol Ther; 2010 Jul; 6(4):240-7. PubMed ID: 20554257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: access to ESRD treatments.
    Hörl WH; de Alvaro F; Williams PF
    Nephrol Dial Transplant; 1999; 14 Suppl 6():10-5. PubMed ID: 10528707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.